The antimigraine agent alniditan selectively constricts porcine carotid arteriovenous anastomoses via 5-HT(1B/1D) receptors

European Journal of Pharmacology

Volumn 351, Issue 2, 1998, Pages 193-201

  De Vries, Peter ^a   Willems, Edwin W ^a   Heiligers, Jan P C ^a   Villalón, Carlos M ^b   Saxena, Pramod R ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

Author keywords

5 HT(1B 1D) receptor; Alniditan; Antimigraine drug; Arteriovenous anastomosis; Carotid artery; GR127935; Migraine; Pig

Indexed keywords

ALNIDITAN; ANTIMIGRAINE AGENT; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; SEROTONIN 1B RECEPTOR; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ARTERIOVENOUS FISTULA; ARTICLE; BLOOD GAS; BRADYCARDIA; CAROTID ARTERY; CAROTID ARTERY FLOW; CONDUCTANCE; CONTROLLED STUDY; DOSE RESPONSE; HEART RATE; HEMODYNAMICS; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; SWINE; VASOCONSTRICTION; VENOUS OXYGEN TENSION;

ANALGESICS; ANIMALS; ARTERIOVENOUS ANASTOMOSIS; BENZOPYRANS; CAROTID ARTERIES; HEMODYNAMIC PROCESSES; HUMANS; JUGULAR VEINS; MALE; MIGRAINE DISORDERS; OXADIAZOLES; OXYGEN; PIPERAZINES; PROPYLAMINES; PYRIMIDINES; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SWINE; VASOCONSTRICTOR AGENTS;

EID: 0031837326     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00301-X     Document Type: Article

References (40)

1. 1D receptors in the brain and trigeminal ganglia, measurement of receptor occupancy in the guinea-pig brain treated with alniditan, sumatriptan and dihydroergotamine. Cephalalgia 17, 399.
2. Bouchelet, I., Cohen, Z., Case, B., Seguela, P., Hamel, E., 1996. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol. Pharmacol. 50, 219-223.
3. 1D antagonists. J. Med. Chem. 37, 2253-2257.
4. (r)) trial (ALN-INT-12 * ) re-assessed using a more stringent efficacy end-point: 24 h pain-free. Cephalalgia 17, 428.
5. 1D receptor antagonist. Br. J. Pharmacol. 118, 85-92.
6. 1B/D receptor ligand, with functional 5-HT receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 355, 423-430.
7. 1B/1D and novel receptors. Br. J. Pharmacol. 123, 1561-1570.
8. 1-like receptors in the reduction of porcine cranial arteriovenous anastomotic shunting by sumatriptan. Br. J. Pharmacol. 102, 323-330.
9. Den Boer, M.O., Van Woerkens, L.J., Somers, J.A., Duncker, D.J., Lachmann, B., Saxena, P.R., Verdouw, P.D., 1993. On the preservation and regulation of vascular tone in arteriovenous anastomoses during anaesthesia. J. Appl. Physiol. 75, 782-789.
10. 1A receptor agonist flesinoxan in the cat. J. Cardiovasc. Pharmacol. 14, 770-776.
11. Feniuk, W., Humphrey, P.P.A., Perren, M.J., 1989. The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs. Br. J. Pharmacol. 96, 83-90.
12. Ferrari, M.D., Saxena, P.R., 1993. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol. Sci. 14, 129-133.
13. Goldstein, J., Dahlöf, C.G.H., Diener, H.C., Olesen, J., Schellens, R., Senard, J.M., Simard, D., Steiner, T.J., 1996. Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Cephalalgia 16, 497-502.
14. Heyck, H., 1969. Pathogenesis of migraine. Res. Clin. Stud. Headache 2, 1-28.
15. Hoyer, D., Clarke, D.E., Fozard, J.R., Hartig, P.R., Martin, G.R., Mylecharane, E.J., Saxena, P.R., Humphrey, P.P.A., 1994. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol. Rev. 46, 157-203.
16. 1-like receptor in dog isolated saphenous vein. Br. J. Pharmacol. 94, 1123-1132.
17. Humphrey, P.P.A., Apperley, E., Feniuk, W., Perren, M.J., 1990. A rational approach to identifying a fundamentally new drug for the treatment of migraine. In: Saxena, P.R., Wallis, D.I., Wouters, W., Bevan, P. (Eds.), Cardiovascular Pharmacology of 5-Hydroxytryptamine: Prospective Therapeutic Applications. Kluwer Academic Publishers, Dordrecht, pp. 416-431.
18. Janssens, W.J., Cools, F., Proost, F., Geyskens, D., Verrelst, J., 1997. Selectivity of alniditan towards isolated cerebral arteries. Cephalalgia 17, 394.
19. 3H]alniditan. Mol. Pharmacol. 50, 1567-1580.
20. 1B/D-receptors in anesthetized rats more effectively than sumatriptan. Cephalalgia 17, 402.
21. 1B/D receptor antagonist GR127935. CNS Drug Rev. 2, 415-428.
22. 1D receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 356, 312-320.
23. Saxena, P.R., 1995. Cranial arteriovenous shunting, an in vivo animal model for migraine. In: Olesen, J., Moskowitz, M.A. (Eds.), Experimental Headache Models. Lippincott-Raven Publishers, Philadelphia, pp. 189-198.
24. Saxena, P.R., Tfelt-Hansen, P., 1993. Sumatriptan. In: Olesen, J., Tfelt-Hansen, P., Welch, K.M.A. (Eds.), The Headaches. Raven Press, New York, pp. 329-341.
25. Saxena, P.R., Verdouw, P.D., 1982. Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous anastomotic blood flow. J. Physiol. 332, 501-520.
26. Saxena, P.R., Villalón, C.M., 1990. Cardiovascular effects of serotonin agonists and antagonists. J. Cardiovasc. Pharmacol. 15, S17-34.
27. Saxena, P.R., Schamhardt, H.C., Forsyth, R.P., Hoeve, J., 1980. Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comput. Prog. Biomed. 12, 63-84.
28. Saxena, P.R., De Vries, P., Heiligers, J.P.C., Maassen Van Den Brink, A., Bax, W.A., Barf, T., Wikström, H., 1996a. Investigations with GMC2021 in experimental models predictive of antimigraine activity and coronary side-effect potential. Eur. J. Pharmacol. 312, 53-62.
29. Saxena, P.R., Maassen Van Den Brink, A., Heiligers, J.P.C., Scalbert, E., Lemaître, B.G., 1996b. Effects of S20749, a close analogue of sumatriptan, on porcine carotid haemodynamics and human isolated coronary artery. Pharmacol. Toxicol. 79, 199-204.
30. 1B/D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential. Naunyn-Schmiedeberg's Arch. Pharmacol. 355, 295-302.
31. 1D receptor agonists in development for the acute treatment of migraine. In: Olesen, J., Tfelt-Hansen, P. (Eds.), Headache Treatment: Trial Methodology and New Drugs. Lippincott-Raven Publishers, New York, pp. 229-241.
32. 1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 356, 321-327.
33. 1D receptor subtype. J. Pharmacol. Exp. Ther. 252, 387-395.
34. 1D receptor antagonist. Behav. Brain Res. 73, 157-161.
35. Steel, R.G.D., Torrie, J.H., 1980. Principles and Procedures of Statistics. A Biomedical Approach, 2nd edn. McGraw-Hill, Kogakusha, Tokyo.
36. The Subcutaneous Sumatriptan International Study Group, 1991. Treatment of migraine attacks with sumatriptan. New Engl. J. Med. 325, 316-321.
37. Van de Water, A., D'Aubioul, J., Van Gerven, W., Van Ammel, K., De Clerck, F., 1996. Selective vasoconstriction by alniditan in the carotid vascular bed of anaesthetized dogs. Eur. J. Pharmacol. 299, 127-137.
38. 1D receptor subtype. Naunyn-Schmiedeberg's Arch. Pharmacol. 354, 550-556.
39. Villalón, C.M., De Vries, P., Saxena, P.R., 1997. Serotonin receptors as cardiovascular targets. Drug Disc. Today 2, 294-300.
40. Visser, W.H., De Vriend, R.H., Jaspers, M.W., Ferrari, M.D., 1996. Sumatriptan in clinical practice: a 2-year review of 453 migraine patients. Neurology 47, 46-51.